PharmacyCodes



Neulasta (Amgen Inc.) en es it fr

Neulasta (Amgen Inc.) Brand names, Neulasta (Amgen Inc.) Analogs

Neulasta (Amgen Inc.) Brand Names Mixture

  • No information avaliable

Neulasta (Amgen Inc.) Chemical_Formula

C845H1343N223O243S9

Neulasta (Amgen Inc.) RX_link

http://www.rxlist.com/cgi/generic3/neulasta.htm

Neulasta (Amgen Inc.) fda sheet

Neulasta (Amgen Inc.) msds (material safety sheet)

Neulasta (Amgen Inc.) Synthesis Reference

No information avaliable

Neulasta (Amgen Inc.) Molecular Weight

18802.8

Neulasta (Amgen Inc.) Melting Point

60 oC (Luo, P., Protein Science 11:1218-1226 (2002))

Neulasta (Amgen Inc.) H2O Solubility

No information avaliable

Neulasta (Amgen Inc.) State

Liquid

Neulasta (Amgen Inc.) LogP

0.209

Neulasta (Amgen Inc.) Dosage Forms

Solution

Neulasta (Amgen Inc.) Indication

Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant

Neulasta (Amgen Inc.) Pharmacology

Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Pegfilgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo as compared to Filgrastim.

Neulasta (Amgen Inc.) Absorption

No information avaliable

Neulasta (Amgen Inc.) side effects and Toxicity

No information avaliable

Neulasta (Amgen Inc.) Patient Information

BIOD00094.html

Neulasta (Amgen Inc.) Organisms Affected

No information avaliable